BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36366956)

  • 1. Differential response in patients with large cell neuroendocrine carcinoma of the lung to initial therapy: A case series.
    Takahara Y; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Sakuma T; Nishiki K; Nakase K; Nojiri M; Kato R; Shinomiya S; Oikawa T; Mizuno S
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1754. PubMed ID: 36366956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
    Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
    Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
    J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
    Sun JM; Ahn MJ; Ahn JS; Um SW; Kim H; Kim HK; Choi YS; Han J; Kim J; Kwon OJ; Shim YM; Park K
    Lung Cancer; 2012 Aug; 77(2):365-70. PubMed ID: 22579297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
    Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
    Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
    BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment for neuroendocrine non-small cell lung carcinoma: A cases series and a systematic review of the literature.
    Jelli B; Brandão M; Mekinda Z; Durieux V; Berghmans T
    Lung Cancer; 2023 Jul; 181():107232. PubMed ID: 37216840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
    Naidoo J; Santos-Zabala ML; Iyriboz T; Woo KM; Sima CS; Fiore JJ; Kris MG; Riely GJ; Lito P; Iqbal A; Veach S; Smith-Marrone S; Sarkaria IS; Krug LM; Rudin CM; Travis WD; Rekhtman N; Pietanza MC
    Clin Lung Cancer; 2016 Sep; 17(5):e121-e129. PubMed ID: 26898325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
    Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
    Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
    Vrontis K; Economidou SC; Fotopoulos G
    Cancer Invest; 2022 Feb; 40(2):124-131. PubMed ID: 34601985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Kinslow CJ; May MS; Saqi A; Shu CA; Chaudhary KR; Wang TJC; Cheng SK
    Clin Lung Cancer; 2020 Mar; 21(2):e99-e113. PubMed ID: 31601526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
    Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
    Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study.
    Song L; Zhou F; Xu T; Zeng L; Xia Q; Wang Z; Deng L; Li Y; Qin H; Yan H; Huang Z; Mi J; Xu Q; Yang N; Zhou C; Zhang Y
    BMC Cancer; 2023 May; 23(1):443. PubMed ID: 37189075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
    Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
    Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC).
    Recuero E; Lázaro S; Lorz C; Enguita AB; Garcia-Escudero R; Santos M
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401).
    Kawabe T; Yamamoto M; Sato Y; Yomo S; Kondoh T; Nagano O; Serizawa T; Tsugawa T; Okamoto H; Akabane A; Aita K; Sato M; Jokura H; Kawagishi J; Shuto T; Kawai H; Moriki A; Kenai H; Iwai Y; Gondo M; Hasegawa T; Yasuda S; Kikuchi Y; Nagatomo Y; Watanabe S; Hashimoto N
    J Neurosurg; 2016 Dec; 125(Suppl 1):11-17. PubMed ID: 27903179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of large cell neuroendocrine carcinoma: a population-based overview.
    Derks JL; Hendriks LE; Buikhuisen WA; Groen HJ; Thunnissen E; van Suylen RJ; Houben R; Damhuis RA; Speel EJ; Dingemans AM
    Eur Respir J; 2016 Feb; 47(2):615-24. PubMed ID: 26541538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
    Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
    Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center.
    Popov P; Steindl A; Wolff L; Bergen ES; Eckert F; Frischer JM; Widhalm G; Fuereder T; Raderer M; Berghoff AS; Preusser M; Kiesewetter B
    Clin Exp Metastasis; 2024 Feb; 41(1):25-32. PubMed ID: 38064128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.